1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Haemophilus Parasuis Bivalent Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Haemophilus Parasuis Bivalent Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Haemophilus Parasuis Bivalent Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Haemophilus Parasuis Bivalent Vaccine Segment by Type
2.2.1 Bivalent Inactivated Vaccine
2.2.2 Trivalent Inactivated Vaccine
2.2.3 Quadrivalent Inactivated Vaccine
2.3 Haemophilus Parasuis Bivalent Vaccine Sales by Type
2.3.1 Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Haemophilus Parasuis Bivalent Vaccine Sale Price by Type (2018-2023)
2.4 Haemophilus Parasuis Bivalent Vaccine Segment by Application
2.4.1 Piglets
2.4.2 Adults Pigs
2.5 Haemophilus Parasuis Bivalent Vaccine Sales by Application
2.5.1 Global Haemophilus Parasuis Bivalent Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Haemophilus Parasuis Bivalent Vaccine Sale Price by Application (2018-2023)
3 Global Haemophilus Parasuis Bivalent Vaccine by Company
3.1 Global Haemophilus Parasuis Bivalent Vaccine Breakdown Data by Company
3.1.1 Global Haemophilus Parasuis Bivalent Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Haemophilus Parasuis Bivalent Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Company (2018-2023)
3.2.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Haemophilus Parasuis Bivalent Vaccine Sale Price by Company
3.4 Key Manufacturers Haemophilus Parasuis Bivalent Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Haemophilus Parasuis Bivalent Vaccine Product Location Distribution
3.4.2 Players Haemophilus Parasuis Bivalent Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Haemophilus Parasuis Bivalent Vaccine by Geographic Region
4.1 World Historic Haemophilus Parasuis Bivalent Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Haemophilus Parasuis Bivalent Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Haemophilus Parasuis Bivalent Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Haemophilus Parasuis Bivalent Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Haemophilus Parasuis Bivalent Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Haemophilus Parasuis Bivalent Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Haemophilus Parasuis Bivalent Vaccine Sales Growth
4.4 APAC Haemophilus Parasuis Bivalent Vaccine Sales Growth
4.5 Europe Haemophilus Parasuis Bivalent Vaccine Sales Growth
4.6 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales Growth
5 Americas
5.1 Americas Haemophilus Parasuis Bivalent Vaccine Sales by Country
5.1.1 Americas Haemophilus Parasuis Bivalent Vaccine Sales by Country (2018-2023)
5.1.2 Americas Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2018-2023)
5.2 Americas Haemophilus Parasuis Bivalent Vaccine Sales by Type
5.3 Americas Haemophilus Parasuis Bivalent Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Haemophilus Parasuis Bivalent Vaccine Sales by Region
6.1.1 APAC Haemophilus Parasuis Bivalent Vaccine Sales by Region (2018-2023)
6.1.2 APAC Haemophilus Parasuis Bivalent Vaccine Revenue by Region (2018-2023)
6.2 APAC Haemophilus Parasuis Bivalent Vaccine Sales by Type
6.3 APAC Haemophilus Parasuis Bivalent Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Haemophilus Parasuis Bivalent Vaccine by Country
7.1.1 Europe Haemophilus Parasuis Bivalent Vaccine Sales by Country (2018-2023)
7.1.2 Europe Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2018-2023)
7.2 Europe Haemophilus Parasuis Bivalent Vaccine Sales by Type
7.3 Europe Haemophilus Parasuis Bivalent Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine by Country
8.1.1 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales by Type
8.3 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Haemophilus Parasuis Bivalent Vaccine
10.3 Manufacturing Process Analysis of Haemophilus Parasuis Bivalent Vaccine
10.4 Industry Chain Structure of Haemophilus Parasuis Bivalent Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Haemophilus Parasuis Bivalent Vaccine Distributors
11.3 Haemophilus Parasuis Bivalent Vaccine Customer
12 World Forecast Review for Haemophilus Parasuis Bivalent Vaccine by Geographic Region
12.1 Global Haemophilus Parasuis Bivalent Vaccine Market Size Forecast by Region
12.1.1 Global Haemophilus Parasuis Bivalent Vaccine Forecast by Region (2024-2029)
12.1.2 Global Haemophilus Parasuis Bivalent Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Haemophilus Parasuis Bivalent Vaccine Forecast by Type
12.7 Global Haemophilus Parasuis Bivalent Vaccine Forecast by Application
13 Key Players Analysis
13.1 Zoetis
13.1.1 Zoetis Company Information
13.1.2 Zoetis Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.1.3 Zoetis Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Zoetis Main Business Overview
13.1.5 Zoetis Latest Developments
13.2 Boehringer-Ingelheim
13.2.1 Boehringer-Ingelheim Company Information
13.2.2 Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.2.3 Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Boehringer-Ingelheim Main Business Overview
13.2.5 Boehringer-Ingelheim Latest Developments
13.3 Eurovet
13.3.1 Eurovet Company Information
13.3.2 Eurovet Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.3.3 Eurovet Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Eurovet Main Business Overview
13.3.5 Eurovet Latest Developments
13.4 Hipra
13.4.1 Hipra Company Information
13.4.2 Hipra Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.4.3 Hipra Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Hipra Main Business Overview
13.4.5 Hipra Latest Developments
13.5 Nisseiken
13.5.1 Nisseiken Company Information
13.5.2 Nisseiken Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.5.3 Nisseiken Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Nisseiken Main Business Overview
13.5.5 Nisseiken Latest Developments
13.6 Merck Animal Health
13.6.1 Merck Animal Health Company Information
13.6.2 Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.6.3 Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Merck Animal Health Main Business Overview
13.6.5 Merck Animal Health Latest Developments
13.7 SPAH
13.7.1 SPAH Company Information
13.7.2 SPAH Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.7.3 SPAH Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 SPAH Main Business Overview
13.7.5 SPAH Latest Developments
13.8 Pulike Biological Engineering
13.8.1 Pulike Biological Engineering Company Information
13.8.2 Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.8.3 Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Pulike Biological Engineering Main Business Overview
13.8.5 Pulike Biological Engineering Latest Developments
13.9 China Animal Husbandry Industry
13.9.1 China Animal Husbandry Industry Company Information
13.9.2 China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.9.3 China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 China Animal Husbandry Industry Main Business Overview
13.9.5 China Animal Husbandry Industry Latest Developments
13.10 Wuhan Keqian Biology
13.10.1 Wuhan Keqian Biology Company Information
13.10.2 Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.10.3 Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Wuhan Keqian Biology Main Business Overview
13.10.5 Wuhan Keqian Biology Latest Developments
13.11 Wo Hua Biotech
13.11.1 Wo Hua Biotech Company Information
13.11.2 Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.11.3 Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Wo Hua Biotech Main Business Overview
13.11.5 Wo Hua Biotech Latest Developments
13.12 Zhejiang Ceva Ebvac Biotech
13.12.1 Zhejiang Ceva Ebvac Biotech Company Information
13.12.2 Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.12.3 Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Zhejiang Ceva Ebvac Biotech Main Business Overview
13.12.5 Zhejiang Ceva Ebvac Biotech Latest Developments
13.13 Luoyang Huizhong Biotech
13.13.1 Luoyang Huizhong Biotech Company Information
13.13.2 Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.13.3 Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Luoyang Huizhong Biotech Main Business Overview
13.13.5 Luoyang Huizhong Biotech Latest Developments
13.14 Beijing Centrebio Biology
13.14.1 Beijing Centrebio Biology Company Information
13.14.2 Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.14.3 Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Beijing Centrebio Biology Main Business Overview
13.14.5 Beijing Centrebio Biology Latest Developments
13.15 Shandong Huahong Bioengineering
13.15.1 Shandong Huahong Bioengineering Company Information
13.15.2 Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.15.3 Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Shandong Huahong Bioengineering Main Business Overview
13.15.5 Shandong Huahong Bioengineering Latest Developments
13.16 Ringpu
13.16.1 Ringpu Company Information
13.16.2 Ringpu Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
13.16.3 Ringpu Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Ringpu Main Business Overview
13.16.5 Ringpu Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Haemophilus Parasuis Bivalent Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Haemophilus Parasuis Bivalent Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Bivalent Inactivated Vaccine
Table 4. Major Players of Trivalent Inactivated Vaccine
Table 5. Major Players of Quadrivalent Inactivated Vaccine
Table 6. Global Haemophilus Parasuis Bivalent Vaccine Sales by Type (2018-2023) & (K Doses)
Table 7. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Type (2018-2023)
Table 8. Global Haemophilus Parasuis Bivalent Vaccine Revenue by Type (2018-2023) & ($ million)
Table 9. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Type (2018-2023)
Table 10. Global Haemophilus Parasuis Bivalent Vaccine Sale Price by Type (2018-2023) & (US$/Dose)
Table 11. Global Haemophilus Parasuis Bivalent Vaccine Sales by Application (2018-2023) & (K Doses)
Table 12. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Application (2018-2023)
Table 13. Global Haemophilus Parasuis Bivalent Vaccine Revenue by Application (2018-2023)
Table 14. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Application (2018-2023)
Table 15. Global Haemophilus Parasuis Bivalent Vaccine Sale Price by Application (2018-2023) & (US$/Dose)
Table 16. Global Haemophilus Parasuis Bivalent Vaccine Sales by Company (2018-2023) & (K Doses)
Table 17. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Company (2018-2023)
Table 18. Global Haemophilus Parasuis Bivalent Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Company (2018-2023)
Table 20. Global Haemophilus Parasuis Bivalent Vaccine Sale Price by Company (2018-2023) & (US$/Dose)
Table 21. Key Manufacturers Haemophilus Parasuis Bivalent Vaccine Producing Area Distribution and Sales Area
Table 22. Players Haemophilus Parasuis Bivalent Vaccine Products Offered
Table 23. Haemophilus Parasuis Bivalent Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Haemophilus Parasuis Bivalent Vaccine Sales by Geographic Region (2018-2023) & (K Doses)
Table 27. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share Geographic Region (2018-2023)
Table 28. Global Haemophilus Parasuis Bivalent Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Haemophilus Parasuis Bivalent Vaccine Sales by Country/Region (2018-2023) & (K Doses)
Table 31. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Country/Region (2018-2023)
Table 32. Global Haemophilus Parasuis Bivalent Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Haemophilus Parasuis Bivalent Vaccine Sales by Country (2018-2023) & (K Doses)
Table 35. Americas Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Country (2018-2023)
Table 36. Americas Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Country (2018-2023)
Table 38. Americas Haemophilus Parasuis Bivalent Vaccine Sales by Type (2018-2023) & (K Doses)
Table 39. Americas Haemophilus Parasuis Bivalent Vaccine Sales by Application (2018-2023) & (K Doses)
Table 40. APAC Haemophilus Parasuis Bivalent Vaccine Sales by Region (2018-2023) & (K Doses)
Table 41. APAC Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Region (2018-2023)
Table 42. APAC Haemophilus Parasuis Bivalent Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Region (2018-2023)
Table 44. APAC Haemophilus Parasuis Bivalent Vaccine Sales by Type (2018-2023) & (K Doses)
Table 45. APAC Haemophilus Parasuis Bivalent Vaccine Sales by Application (2018-2023) & (K Doses)
Table 46. Europe Haemophilus Parasuis Bivalent Vaccine Sales by Country (2018-2023) & (K Doses)
Table 47. Europe Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Country (2018-2023)
Table 48. Europe Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Country (2018-2023)
Table 50. Europe Haemophilus Parasuis Bivalent Vaccine Sales by Type (2018-2023) & (K Doses)
Table 51. Europe Haemophilus Parasuis Bivalent Vaccine Sales by Application (2018-2023) & (K Doses)
Table 52. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales by Country (2018-2023) & (K Doses)
Table 53. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales by Type (2018-2023) & (K Doses)
Table 57. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales by Application (2018-2023) & (K Doses)
Table 58. Key Market Drivers & Growth Opportunities of Haemophilus Parasuis Bivalent Vaccine
Table 59. Key Market Challenges & Risks of Haemophilus Parasuis Bivalent Vaccine
Table 60. Key Industry Trends of Haemophilus Parasuis Bivalent Vaccine
Table 61. Haemophilus Parasuis Bivalent Vaccine Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Haemophilus Parasuis Bivalent Vaccine Distributors List
Table 64. Haemophilus Parasuis Bivalent Vaccine Customer List
Table 65. Global Haemophilus Parasuis Bivalent Vaccine Sales Forecast by Region (2024-2029) & (K Doses)
Table 66. Global Haemophilus Parasuis Bivalent Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Haemophilus Parasuis Bivalent Vaccine Sales Forecast by Country (2024-2029) & (K Doses)
Table 68. Americas Haemophilus Parasuis Bivalent Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Haemophilus Parasuis Bivalent Vaccine Sales Forecast by Region (2024-2029) & (K Doses)
Table 70. APAC Haemophilus Parasuis Bivalent Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Haemophilus Parasuis Bivalent Vaccine Sales Forecast by Country (2024-2029) & (K Doses)
Table 72. Europe Haemophilus Parasuis Bivalent Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales Forecast by Country (2024-2029) & (K Doses)
Table 74. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Haemophilus Parasuis Bivalent Vaccine Sales Forecast by Type (2024-2029) & (K Doses)
Table 76. Global Haemophilus Parasuis Bivalent Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Haemophilus Parasuis Bivalent Vaccine Sales Forecast by Application (2024-2029) & (K Doses)
Table 78. Global Haemophilus Parasuis Bivalent Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Zoetis Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. Zoetis Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 81. Zoetis Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 82. Zoetis Main Business
Table 83. Zoetis Latest Developments
Table 84. Boehringer-Ingelheim Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 86. Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 87. Boehringer-Ingelheim Main Business
Table 88. Boehringer-Ingelheim Latest Developments
Table 89. Eurovet Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Eurovet Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 91. Eurovet Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 92. Eurovet Main Business
Table 93. Eurovet Latest Developments
Table 94. Hipra Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Hipra Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 96. Hipra Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 97. Hipra Main Business
Table 98. Hipra Latest Developments
Table 99. Nisseiken Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Nisseiken Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 101. Nisseiken Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 102. Nisseiken Main Business
Table 103. Nisseiken Latest Developments
Table 104. Merck Animal Health Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 106. Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 107. Merck Animal Health Main Business
Table 108. Merck Animal Health Latest Developments
Table 109. SPAH Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. SPAH Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 111. SPAH Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 112. SPAH Main Business
Table 113. SPAH Latest Developments
Table 114. Pulike Biological Engineering Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 116. Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 117. Pulike Biological Engineering Main Business
Table 118. Pulike Biological Engineering Latest Developments
Table 119. China Animal Husbandry Industry Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 121. China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 122. China Animal Husbandry Industry Main Business
Table 123. China Animal Husbandry Industry Latest Developments
Table 124. Wuhan Keqian Biology Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 126. Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 127. Wuhan Keqian Biology Main Business
Table 128. Wuhan Keqian Biology Latest Developments
Table 129. Wo Hua Biotech Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 131. Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 132. Wo Hua Biotech Main Business
Table 133. Wo Hua Biotech Latest Developments
Table 134. Zhejiang Ceva Ebvac Biotech Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 136. Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 137. Zhejiang Ceva Ebvac Biotech Main Business
Table 138. Zhejiang Ceva Ebvac Biotech Latest Developments
Table 139. Luoyang Huizhong Biotech Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 141. Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 142. Luoyang Huizhong Biotech Main Business
Table 143. Luoyang Huizhong Biotech Latest Developments
Table 144. Beijing Centrebio Biology Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 146. Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 147. Beijing Centrebio Biology Main Business
Table 148. Beijing Centrebio Biology Latest Developments
Table 149. Shandong Huahong Bioengineering Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 150. Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 151. Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 152. Shandong Huahong Bioengineering Main Business
Table 153. Shandong Huahong Bioengineering Latest Developments
Table 154. Ringpu Basic Information, Haemophilus Parasuis Bivalent Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 155. Ringpu Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications
Table 156. Ringpu Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 157. Ringpu Main Business
Table 158. Ringpu Latest Developments
List of Figures
Figure 1. Picture of Haemophilus Parasuis Bivalent Vaccine
Figure 2. Haemophilus Parasuis Bivalent Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Haemophilus Parasuis Bivalent Vaccine Sales Growth Rate 2018-2029 (K Doses)
Figure 7. Global Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Haemophilus Parasuis Bivalent Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Bivalent Inactivated Vaccine
Figure 10. Product Picture of Trivalent Inactivated Vaccine
Figure 11. Product Picture of Quadrivalent Inactivated Vaccine
Figure 12. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Type in 2022
Figure 13. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Type (2018-2023)
Figure 14. Haemophilus Parasuis Bivalent Vaccine Consumed in Piglets
Figure 15. Global Haemophilus Parasuis Bivalent Vaccine Market: Piglets (2018-2023) & (K Doses)
Figure 16. Haemophilus Parasuis Bivalent Vaccine Consumed in Adults Pigs
Figure 17. Global Haemophilus Parasuis Bivalent Vaccine Market: Adults Pigs (2018-2023) & (K Doses)
Figure 18. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Application (2022)
Figure 19. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Application in 2022
Figure 20. Haemophilus Parasuis Bivalent Vaccine Sales Market by Company in 2022 (K Doses)
Figure 21. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Company in 2022
Figure 22. Haemophilus Parasuis Bivalent Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 23. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Company in 2022
Figure 24. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Geographic Region in 2022
Figure 26. Americas Haemophilus Parasuis Bivalent Vaccine Sales 2018-2023 (K Doses)
Figure 27. Americas Haemophilus Parasuis Bivalent Vaccine Revenue 2018-2023 ($ Millions)
Figure 28. APAC Haemophilus Parasuis Bivalent Vaccine Sales 2018-2023 (K Doses)
Figure 29. APAC Haemophilus Parasuis Bivalent Vaccine Revenue 2018-2023 ($ Millions)
Figure 30. Europe Haemophilus Parasuis Bivalent Vaccine Sales 2018-2023 (K Doses)
Figure 31. Europe Haemophilus Parasuis Bivalent Vaccine Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales 2018-2023 (K Doses)
Figure 33. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Revenue 2018-2023 ($ Millions)
Figure 34. Americas Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Country in 2022
Figure 35. Americas Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Country in 2022
Figure 36. Americas Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Type (2018-2023)
Figure 37. Americas Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Application (2018-2023)
Figure 38. United States Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Region in 2022
Figure 43. APAC Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Regions in 2022
Figure 44. APAC Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Type (2018-2023)
Figure 45. APAC Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Application (2018-2023)
Figure 46. China Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. India Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Country in 2022
Figure 54. Europe Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Country in 2022
Figure 55. Europe Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Type (2018-2023)
Figure 56. Europe Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Application (2018-2023)
Figure 57. Germany Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 58. France Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Country in 2022
Figure 63. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Application (2018-2023)
Figure 66. Egypt Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country Haemophilus Parasuis Bivalent Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Haemophilus Parasuis Bivalent Vaccine in 2022
Figure 72. Manufacturing Process Analysis of Haemophilus Parasuis Bivalent Vaccine
Figure 73. Industry Chain Structure of Haemophilus Parasuis Bivalent Vaccine
Figure 74. Channels of Distribution
Figure 75. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Forecast by Region (2024-2029)
Figure 76. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share Forecast by Application (2024-2029)

※参考情報 ヘモフィルス・パラスイス二価ワクチン（Haemophilus parasuis bivalent vaccine）は、豚の感染症予防に使用される重要なワクチンです。このワクチンは、ヘモフィルス・パラスイスという細菌によって引き起こされる病気の予防を目的としており、特に豚の健康管理において重要な役割を果たしています。 ヘモフィルス・パラスイスは、グラム陰性の細菌であり、主に豚に影響を与えます。この細菌は、特に生後数週間から数ヶ月の間の子豚に感染しやすく、壊死性肺炎や関節炎、髄膜炎など、さまざまな重篤な症状を引き起こす可能性があります。これにより、経済的な損失が生じるため、ヘモフィルス・パラスイスに対する予防接種は畜産業界において非常に重要です。 二価ワクチンとは、異なる2種類の抗原を含むワクチンであり、特定の病原体に対する免疫応答を誘発します。ヘモフィルス・パラスイス二価ワクチンでは、異なる株のヘモフィルス・パラスイスに対する抗原が含まれており、これにより広範囲な免疫を獲得することができます。このワクチンの主な特徴は、さまざまな異なるヘモフィルス・パラスイスの株に対して効果的である点です。これにより、特定の地域や飼育環境における感染リスクを軽減することが可能になります。 ワクチンの種類には、主に不活化ワクチンと生ワクチンがあります。不活化ワクチンは、病原体を殺して逆に免疫応答を引き起こす形式で、一方、生ワクチンは病原体を弱毒化したものを使用します。ヘモフィルス・パラスイス二価ワクチンは通常、不活化ワクチンとして製造されています。不活化ワクチンの利点としては、感染を引き起こすリスクが低く、安全性が高いため、特に家畜に対して適切な選択となる点が挙げられます。 このワクチンの用途は主に、健康な豚への予防接種です。感染症の発生を未然に防ぐことで、飼育環境の安定化を図るとともに、農業経済の安定にも寄与しています。予防接種は、一般的に子豚の生後数週間から数ヶ月の時期に行われることが多く、接種後は特定の期間中に免疫が形成され、感染症への耐性が高まります。 関連技術としては、遺伝子工学やワクチン製造に関する新しい研究開発が進んでいます。近年、分子生物学や遺伝子工学の技術を応用し、より効果的なワクチンの開発が行われています。これにより、免疫学的応答が向上し、副作用の少ないワクチンの開発が期待されています。また、これらの新しい技術は、従来の製造方法を補完し、ワクチン開発の効率化にも寄与しています。 ヘモフィルス・パラスイス二価ワクチンは、豚の健康を守るだけでなく、畜産業の経済的利益に直結するため、投資価値の高い製品です。適切な時期に接種を行うことで、感染症による損失を大幅に軽減することが可能です。また、農家や畜産業者にとっては、健康で成長の早い豚を育てることができるため、重要な選択肢とされています。 さらに、このワクチンに関連した研究も進んでおり、今後の発展が期待されています。特に、豚の免疫機構に関する理解が深まることで、より効果的な予防策が確立される可能性があります。また、他の病原体に対するワクチン開発も進行中であり、全体的な豚の健康管理の枠組みが拡充されることが見込まれます。 まとめると、ヘモフィルス・パラスイス二価ワクチンは、豚に対する重要な予防接種の一環として、多様な株に対して効果を発揮します。これにより、畜産業における感染症の拡大を防ぎ、経済的損失の軽減に寄与する重要なアイテムです。また、革新的な技術を駆使した新しいワクチンの開発が進むことで、豚の健康保持のための手段はさらに多様化していくことでしょう。これにより、畜産業界全体の持続可能な発展が期待されます。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer